Monthly Mifepristone
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): King George's Medical College
Details
- API: Mifepristone
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Regimen: 1 Pill/Month
- MPT: Not Potential MPT
- Promising Attributes: Mifepristone is generally associated with more controlled side effects and broader eligibility than comparable oral alternatives
Product Status
Evaluation has generally shifted to focus on weekly administration of 50mg product, with no indication of active development of a monthly method after 2009
History
2009: King George's Medical University publishes results of prospective case control study finding reasonable efficacy and high user satisfaction and continuation compared to the COC control, but required fixed-date administration.